Sugi Predict

Sugi Predict / Compounds / SCHEMBL20542192

SCHEMBL20542192

SCHEMBL20542192

CC(C)n1cnc2c(NCCc3c[nH]c4ccncc34)nc(Cl)nc21

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 13/20 0.52
▸ CDK5 Q00535 12/20 0.52
▸ CDK5R1 Q15078 12/20 0.52
▸ CCNA2 P20248 9/20 0.52
▸ CCNA1 P78396 9/20 0.52
▸ DYRK1A Q13627 8/20 0.52
▸ CCNE1 P24864 2/20 0.51
▸ CCNE2 O96020 1/20 0.51
▸ CDK1 P06493 2/20 0.50
▸ NPC1 O15118 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ HTR6 P50406 2/20 0.40
▸ CDK9 P50750 2/20 0.40
▸ CDK4 P11802 1/20 0.39
▸ CCNB1 P14635 1/20 0.39
▸ CCND1 P24385 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ CDK7 P50613 1/20 0.39
▸ CCNH P51946 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20558018 0.83 CDK1 (0.54) CDK2CDK5CDK5R1CCNA2CCNA1
SCHEMBL31747035 0.83 CDK2 (0.46) CDK2CDK5CDK5R1CCNE1CCNE2
SCHEMBL20542259 0.83 CDK2 (0.46) CDK2CDK5CDK5R1CCNE1CCNE2
SCHEMBL22566856 0.79 CDK2 (0.45) CDK2CDK5CDK5R1CCNA2CCNA1
SCHEMBL2359490 0.79 CYP1A2 (0.52) CDK2CDK5CDK5R1CCNA2CCNA1
SCHEMBL2319820 0.78 GBA1 (0.64) CDK2CDK5CDK5R1CCNA2CCNE1
SCHEMBL2358849 0.77 CDK2 (0.58) CDK2CCNE1CCNE2CDK1NPC1
SCHEMBL2358538 0.76 CYP1A2 (0.53) CDK2CDK5CDK5R1CCNE1CCNE2
SCHEMBL21754215 0.76 CDK2 (0.46) CDK2CDK5CDK5R1CCNE1CCNE2
SCHEMBL13282305 0.75 CYP1A2 (0.52) CDK2CDK5CDK5R1CCNA2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4710923-A2 INDOLE AHR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2026-03-18 — — EP disclosed
EP-3612030-B1 INDOLE AHR INHIBITORS AND USES THEREOF IKENA ONCOLOGY INC (US) 2025-12-24 — — EP disclosed
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-12077542-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-09-03 — — US disclosed
CN-110831600-B Indole AHR inhibitors and uses thereof 医肯纳肿瘤学公司 2023-10-17 — — CN disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 — — US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 — — US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 — — US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 — — US disclosed
EP-3612030-A2 INDOLE AHR INHIBITORS AND USES THEREOF Kyn Therapeutics (US) 2020-02-26 — — EP disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
CN-110831600-A Indole AHR inhibitors and uses thereof 金恩医疗公司 2020-02-21 — — CN disclosed
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2018-11-15 — — US disclosed
WO-2018195397-A2 INDOLE AHR INHIBITORS AND USES THEREOF KYN THERAPEUTICS (US) 2018-10-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 CDK2 1444/4885CDK5 1931/4885CDK5R1 1393/4885
US-10570138-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 CDK2 1444/4885CDK5 1931/4885CDK5R1 1393/4885
US-11358969-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 CDK2 1444/4885CDK5 1931/4885CDK5R1 1393/4885
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 CDK2 1444/4885CDK5 1931/4885CDK5R1 1393/4885
US-10689388-B1 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 CDK2 1444/4885CDK5 1931/4885CDK5R1 1393/4885
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 CDK2 1444/4885CDK5 1931/4885CDK5R1 1393/4885
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 CDK2 1444/4885CDK5 1931/4885CDK5R1 1393/4885
US-12077542-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 CDK2 1444/4885CDK5 1931/4885CDK5R1 1393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback